ストックスクリーナーアプリを入手
5.9815
4.23%
-0.2885
前日終値:
$6.27
開ける：
$6.25
24時間の取引高:
954.66K
Relative Volume:
0.44
時価総額：
$1.07B
収益：
-
当期純損益:
$-45.44M
株価収益率:
-17.09
EPS:
-0.35
ネットキャッシュフロー:
$-42.28M
1週間 パフォーマンス:
+5.35%
1か月 パフォーマンス:
+16.83%
6か月 パフォーマンス:
+80.33%
1年 パフォーマンス:
+93.71%
1日の値動き範囲:
$5.99
$6.35
1週間の範囲:
$5.50
$6.40
52週間の値動き範囲:
$1.33
$6.40
Compass Therapeutics Inc Stock (CMPX) Company Profile
CMPX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.99 | 1.12B | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | 開始されました | William Blair | Outperform |
| 2025-12-03 | 開始されました | Canaccord Genuity | Buy |
| 2025-12-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-07-01 | 再開されました | Raymond James | Outperform |
| 2025-04-02 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 開始されました | Guggenheim | Buy |
| 2025-02-19 | 開始されました | Piper Sandler | Overweight |
| 2024-12-23 | 開始されました | D. Boral Capital | Buy |
| 2024-11-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 開始されました | Jefferies | Buy |
| 2023-01-27 | 開始されました | Stifel | Buy |
| 2022-05-23 | 再開されました | H.C. Wainwright | Buy |
| 2022-03-15 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-01-19 | 開始されました | B. Riley Securities | Buy |
| 2021-12-22 | 開始されました | Raymond James | Outperform |
| 2021-12-20 | 開始されました | SVB Leerink | Outperform |
| 2021-12-15 | 開始されました | Wedbush | Outperform |
すべてを表示
Compass Therapeutics Inc (CMPX) 最新ニュース
Compass Therapeutics stock hits 52-week high at 6.25 USD By Investing.com - Investing.com Nigeria
Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month HighHere's What Happened - MarketBeat
Compass Therapeutics stock hits 52-week high at 6.25 USD - Investing.com
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026, But Don't Get Too Ahead - Seeking Alpha
Compass Therapeutics, Inc. (CMPX): A Bull Case Theory - Finviz
Is Compass Therapeutics Inc. stock a defensive play in 2025Weekly Investment Summary & Reliable Price Breakout Signals - bollywoodhelpline.com
How Compass Therapeutics Inc. stock reacts to global recession fearsJuly 2025 Analyst Calls & Real-Time Volume Analysis - bollywoodhelpline.com
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Assessing Compass Therapeutics (CMPX) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance
Assessing Compass Therapeutics (CMPX) Valuation After A Year Of Strong Share Price Momentum - Sahm
Aug Catalysts: How does Compass Therapeutics Inc perform in inflationary periods2025 Buyback Activity & Risk Managed Trade Strategies - baoquankhu1.vn
Is Compass Therapeutics (CMPX) Quietly Rewriting Its Oncology Strategy With New Commercial and Medical Chiefs? - Yahoo Finance
Compass Therapeutics (NASDAQ:CMPX) Trading Down 6.8%Time to Sell? - MarketBeat
Will Compass Therapeutics’ (CMPX) New Oncology Leaders Redefine Its Path From Pipeline to Commercial Scale? - Sahm
Compass Therapeutics (NASDAQ:CMPX) Sets New 12-Month HighTime to Buy? - MarketBeat
Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development - MSN
Growth Review: Is Compass Therapeutics Inc stock a top pick in earnings seasonJuly 2025 Summary & Community Consensus Trade Alerts - Bộ Nội Vụ
Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement - MSN
Lifesci Capital Has Strong Estimate for CMPX FY2025 Earnings - Defense World
What is Lifesci Capital's Estimate for CMPX FY2025 Earnings? - MarketBeat
Why Compass Therapeutics Inc. stock could outperform in 2025Market Trend Report & Scalable Portfolio Growth Ideas - Улправда
Will Compass Therapeutics Inc. stock benefit from green energy trendsQuarterly Profit Summary & Low Drawdown Momentum Ideas - ulpravda.ru
Is Compass Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Rallies & Capital Protection Trading Alerts - Улправда
Short Squeeze: Is Compass Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Daily Volume Surge Signals - ulpravda.ru
Will Compass Therapeutics Inc. stock benefit from commodity prices2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
Is Compass Therapeutics Inc. stock supported by strong fundamentals2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - Улправда
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a Biotech Powerhouse with 142.77% Upside Potential - DirectorsTalk Interviews
Why analysts remain bullish on Compass Therapeutics Inc. stock2025 Investor Takeaways & Reliable Entry Point Alerts - ulpravda.ru
Is Compass Therapeutics Inc. stock in correction or buying zoneMarket Capitalization Trends & Reinvest for Maximum Compounding Returns - Улправда
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Compass Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Compass Therapeutics details cash runway and pipeline progress - MSN
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics appoints new chief commercial and medical officers By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Compass Therapeutics stock with $12 target - Investing.com Canada
Raymond James reiterates Outperform rating on Compass Therapeutics stock By Investing.com - Investing.com Canada
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Compass Therapeutics reports progress across cancer drug pipeline By Investing.com - Investing.com South Africa
Compass Therapeutics Provides Corporate Update - The Manila Times
Compass Therapeutics reports progress across cancer drug pipeline - Investing.com
CMPXCompass Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026 - marketscreener.com
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation - Nasdaq
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care - One News Page
Compass Therapeutics announces key leadership appointments - marketscreener.com
Compass Therapeutics appoints new chief commercial and medical officers - Investing.com
Compass Therapeutics Announces Key Leadership Appointments - The Manila Times
William Blair Initiates Compass Therapeutics at Outperform - MarketScreener
William Blair initiates coverage on Compass Therapeutics stock with Outperform rating - Investing.com Canada
Compass Therapeutics Inc (CMPX) 財務データ
収益
当期純利益
現金流量
EPS
4.38%
1.95%
大文字化:
|
ボリューム (24 時間):